Moderna mRNA vaccine prevents melanoma recurrence in trial

Clinical trial results suggest Moderna's personalised mRNA cancer vaccine effectively stops melanoma from returning after treatment. The technology, which trains the immune system to target tumour-specific mutations, could potentially be applied to other cancer types in the future. Researchers say the promising results mark a significant step forward for personalised cancer immunotherapy.

Similar stories

🏥 Health Moderna-Merck personalised melanoma vaccine extends relapse-free survival in first late-stage trial CNBC · 1d ago 📈 Business Moderna shares double on cancer vaccine trial results — Trump earned up to $91,000 Money.pl · 7h ago 🔬 Science Moderna shares double after Phase 3 cancer vaccine breakthrough Decrypt · 1d ago